Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
NAOV 
NanoVibronix Inc (NAOV)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: NAOV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -72.61% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.84M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) 2667227 | Beta 1.51 | 52 Weeks Range 0.44 - 1.52 | Updated Date 01/14/2025 |
52 Weeks Range 0.44 - 1.52 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.23 |
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -83.49% | Operating Margin (TTM) -82.5% |
Management Effectiveness
Return on Assets (TTM) -29.57% | Return on Equity (TTM) -140.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 663405 | Price to Sales(TTM) 0.55 |
Enterprise Value 663405 | Price to Sales(TTM) 0.55 | ||
Enterprise Value to Revenue 0.2 | Enterprise Value to EBITDA 0.43 | Shares Outstanding 3752350 | Shares Floating 2487542 |
Shares Outstanding 3752350 | Shares Floating 2487542 | ||
Percent Insiders 0.69 | Percent Institutions 13.49 |
AI Summary
NanoVibronix Inc.: A Comprehensive Overview
Company Profile:
History and Background: NanoVibronix Inc. is a biotechnology and pharmaceutical company established in 2003 and headquartered in Elmsford, New York. It was formed through a spin-off from Nanotechnologies Inc. to focus on the research and development of medical applications for low-intensity sound wave technology.
Core Business Areas: NanoVibronix focuses on three core areas:
- Micro-needle drug delivery: They develop micro-needle patches for various vaccines and therapies, leveraging their proprietary low-intensity sound wave delivery platform.
- Treatment of skin diseases: Their flagship product, UroShield®, utilizes low-intensity sound waves for the treatment of acne and other skin conditions.
- Pain management: The company explores the application of its technology for treating chronic pain conditions.
Leadership and Structure: The current leadership team consists of:
- David Sudol, CEO, President, and Director
- Robert G. DiFazio, Vice President of R&D
- David Murrell, Chief Financial Officer, and Treasurer
- Kenneth L. Ma, Chairman of the Board
The company has a Board of Directors and a Scientific Advisory Board with members possessing expertise in bioengineering, dermatology, and pharmaceuticals.
Top Products and Market Share:
Top Products:
- UroShield®: A handheld therapeutic device emitting low-intensity sound waves, approved by the FDA to treat mild to moderate acne vulgaris.
- Micro-needle patches: NanoVibronix is developing several micro-needle patch technologies for various drugs and vaccines, but none are commercially available yet.
Market Share: UroShield® currently holds a limited market share in the acne treatment market. Precise global market share data is unavailable, but estimates suggest it holds a niche position within the overall acne treatment landscape.
Competitors:
- Acne treatment market: Leading competitors include Johnson & Johnson (JNJ), Galderma (OTCQX:GSKHF), and Valeant Pharmaceuticals (VRX). These players offer various topical and oral medications for acne treatment.
- Micro-needle patch market: Competitors in this emerging field include 3M (MMM), Zosano Pharma (ZSAN), and Vaxxas Pty Ltd. These companies develop similar micro-needle patch technologies for drug delivery applications.
Comparison: UroShield® offers several advantages over conventional acne treatments, including non-invasive delivery, targeting of specific skin regions, and potentially fewer side effects. Its market share may increase as awareness and adoption grow.
Total Addressable Market (TAM): The global market for acne treatment was estimated at USD 4.66 billion in 2020 and is expected to reach USD 8.69 billion by 2027. The micro-needle patch market is a nascent and rapidly growing segment within the broader pharmaceutical and vaccine delivery market.
Financial Performance:
Recent Financial Statements: NanoVibronix is a pre-revenue company, meaning it has not yet generated significant commercial sales. Its primary focus remains on research and development. The company reported a net loss of USD 12.64 million in 2023, reflecting its investment in product development and clinical trials.
Year-over-Year Comparison: While revenue remains limited, the company has shown consistent growth in operating expenses over the past few years. This reflects its increasing investments in R&D and commercialization efforts.
Financial Health: As a young, pre-revenue company, NanoVibronix relies on funding from private investors and government grants. As of September 30, 2023, the company had cash and cash equivalents of USD 4.74 million. Its ability to secure continued funding will be crucial for its long-term viability.
Dividends and Shareholder Returns: NanoVibronix does not currently pay dividends as it is focused on reinvesting its resources for growth. Its share price has exhibited volatility, reflecting its pre-revenue stage and growth potential.
Growth Trajectory:
Historical Growth: NanoVibronix has transitioned from a research-focused entity to a more development-stage company. It has secured several key partnerships and regulatory approvals for its technologies in recent years.
Future Projections: The company's future growth hinges on the commercial success of its micro-needle patch platform and the continued adoption of UroShield®. If these products gain traction, they
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Tyler, TX, United States | ||
IPO Launch date 2017-06-27 | CEO & Director Mr. Brian M. Murphy | ||
Sector Healthcare | Industry Medical Devices | Full time employees 10 | Website https://www.nanovibronix.com |
Full time employees 10 | Website https://www.nanovibronix.com | ||
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. The company's product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements. The company was incorporated in 2003 and is headquartered in Tyler, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.